The president may be losing control of his narrative Continue reading… source https://finance.yahoo.com/news/trumps-latest-trade-war-tirade-211355057.html?.tsrc=rss

Q2 2019 Vale SA Earnings Call source https://finance.yahoo.com/news/edited-transcript-vale5-sa-earnings-060933766.html?.tsrc=rss

The tech company wants to change how people pay for things. Has it succeeded? source https://finance.yahoo.com/news/hands-apple-credit-card-210500925.html?.tsrc=rss

The basics of banking won’t change much, but they will be turbocharged by technology. source https://finance.yahoo.com/news/where-jpmorgan-chase-5-years-210500580.html?.tsrc=rss

Video game stocks are climbing as the critical holiday season approaches. Top publisher Activision Blizzard led a rally on Tuesday that also lifted Zynga and Take-Two Interactive…… Read more “Video Game Stocks Hopping Ahead Of Holiday Season”

Premier Inc. , a leading healthcare improvement company, announced today that its Chief Executive Officer, Susan DeVore, and Chief Administrative and Financial Officer, Craig McKasson, will present…… Read more “Healthcare Improvement Company Premier Inc. to Present at Baird’s 2019 Global Healthcare Conference in New York on Wednesday, Sept. 4, 2019 at 10:15 a.m. ET”

Wall Street slipped on Tuesday, weighed down by financial stocks as a deepening of the Treasury yield curve inversion raised U.S. recession worries and uncertainty over any…… Read more “US STOCKS-Wall Street slips as financials drag, trade outlook clouds”

Veeva earnings of 55 cents per share on $266.9 million in sales beat estimates Tuesday, leading Veeva stock to pop in late trading. Veeva is a member…… Read more “This IBD 50 Stock Just Crushed Second-Quarter Estimates; Shares Pop”

New Oriental Education stock has nearly doubled in 2019. The IBD Stock Of The Day just formed a new base offering a buy point for new investors.…… Read more “New Oriental Education, IBD Stock Of The Day, Offers New Buy Point After Doubling In 2019”

Median progression-free survival and overall response rate doubled among patients receiving EPd compared to pomalidomide and low-dose dexamethasone alone source https://finance.yahoo.com/news/european-commission-approves-empliciti-elotuzumab-201600166.html?.tsrc=rss